Gadolinium Deposition in the Brain: Current Updates.
- Author:
Jin Woo CHOI
1
;
Won Jin MOON
Author Information
- Publication Type:Review
- Keywords: Pharmacovigilance and Risk Assessment Committee; Ministry of Food and Drug Safety in Korea; Deposition mechanism; Thermodynamic stability; Chelating ligand; Gadoilnium; Brain deposition
- MeSH: Brain*; Contrast Media; Gadolinium*; Magnetic Resonance Imaging; Nephrogenic Fibrosing Dermopathy
- From:Korean Journal of Radiology 2019;20(1):134-147
- CountryRepublic of Korea
- Language:English
- Abstract: Gadolinium-based contrast agents (GBCAs) are commonly used for enhancement in MR imaging and have long been considered safe when administered at recommended doses. However, since the report that nephrogenic systemic fibrosis is linked to the use of GBCAs in subjects with severe renal diseases, accumulating evidence has suggested that GBCAs are not cleared entirely from our bodies; some GBCAs are deposited in our tissues, including the brain. GBCA deposition in the brain is mostly linked to the specific chelate structure of the GBCA: linear GBCAs were responsible for brain deposition in almost all reported studies. This review aimed to summarize the current knowledge about GBCA brain deposition and discuss its clinical implications.
